Cargando…
Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?
Monoclonal antibodies bevacizumab and cetuximab both improve overall survival (OS), progression free survival (PFS) and overall response rate (ORR) when combined with irinotecan-containing regimens. The optimal sequence of these monoclonal antibodies in combination with chemotherapy is controversial...
Autores principales: | Grande, Roberta, Gemma, Donatello, Sperduti, Isabella, Gelibter, Alain, Giampaolo, Maria Anna, Trombetta, Giorgio, Nelli, Fabrizio, Gamucci, Teresa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing AG
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647091/ https://www.ncbi.nlm.nih.gov/pubmed/23667824 http://dx.doi.org/10.1186/2193-1801-2-185 |
Ejemplares similares
-
Evaluation of Relapse-Free Survival in T3N0 Colon Cancer: The Role of Chemotherapy, a Multicentric Retrospective Analysis
por: Grande, Roberta, et al.
Publicado: (2013) -
Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis
por: Grande, Roberta, et al.
Publicado: (2016) -
Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study
por: Siringo, Marco, et al.
Publicado: (2023) -
Keep looking until you find
por: Tuomola, Nelli
Publicado: (2023) -
SERCA2a Protein Levels Are Unaltered in Human Heart Failure
por: Ragone, Isabella, et al.
Publicado: (2023)